Same versus different types of drug-eluting stents in the treatment of in-stent restenosis: A meta analysis

doi:10.3969/j.issn.2095-4344.2013.03.029

Abstract

Abstract:

BACKGROUND: It is still unknown when drug-eluting stent in-stent restenosis happens, which type of drug-eluting stents should be implanted during percutaneous coronary intervention.
OBJECTIVE: To evaluate the efficacy and safety of the same versus different types of drug-eluting stents in treating coronary artery disease patients suffering from in-stent restenosis after first percutaneous coronary intervention using drug-eluting stents.
METHODS: PubMed, EMBASE, Google Scholar Research, Cochrane Library and Chinese BioMedical Literature Database on disc were searched for clinical trials about the same and different types of
drug-eluting stents in treating coronary artery disease patients suffering from in-stent restenosis after first percutaneous coronary intervention using drug-eluting stents. Then, a meta-analysis was performed.
RESULTS AND CONCLUSION: Six articles were enrolled in the meta-analysis, including 983 cases of in-stent restenosis who received sirolimus-eluting stents or paclitaxel-eluting stents re-implantation following first drug-eluting stent implantation. There were no significant differences between the same and different type of re-implanted drug-eluting stents in all-cause mortality (P=0.31, I2=14%, odd ratio (OR)=0.92, 95% confidence index (CI) [0.40,2.08]), secondary myocardial infarction (P=0.64, I²=0, OR=2.68, 95% CI[1.00,7.24]), the incidence of in-stent thrombosis (P=0.82, I²=0, OR=2.02, 95% CI[0.37,11.08]), and target lesion revascularization (P=0.63, I²=0, OR=1.15, 95% CI[0.75,1.76]). Based on the obtained statistical results, there was no difference between the efficacy and safety of the same and different types of drug-eluting stents for treatment of in-stent restenosis following the first percutaneous coronary intervention using drug-eluting stents.

Key words: biomaterials, evidence-based biomaterials, coronary heart diseases, percutaneous coronary intervention, drug-eluting stents, rapamycin (sirolimus)-eluting stents, paclitaxel-eluting stents

CLC Number:

R318

Li Ying, Li Lang, Su Qiang, Kyaw Aung Naing. Same versus different types of drug-eluting stents in the treatment of in-stent restenosis: A meta analysis[J]. Chinese Journal of Tissue Engineering Research, 2013, 17(3): 565-570.

Figures/Tables 6

References

[1] Serruys PW,Degertekin M,Tanabe K,et al. Intravascular ultrasound findings in the multicenter, randomized, double-blind RAVEL (RAndomized study with the sirolimus-eluting VElocity balloon-expandable stent in the treatment of patients with de novo native coronary artery Lesions) trial. Circulation.2002；106(7):798-803.

[2] Holmes DR Jr,Leon MB,Moses JW,et al.Analysis of 1-year clinical outcomes in the SIRIUS trial: a randomized trial of a sirolimus-eluting stent versus a standard stent in patients at high risk for coronary restenosis.Circulation.2004;109(5): 634-640.

[3] Schofer J,Schluter M,Gershlick AH,et al. Sirolimus-eluting stents for treatment of patients with long atherosclerotic lesions in small coronary arteries: double-blind, randomised controlled trial (E-SIRIUS). Lancet.2003;362(9390): 1093-1099.

[4] Ellis SG,Colombo A,Grube E,et al. Incidence, timing, and correlates of stent thrombosis with the polymeric paclitaxel drug-eluting stent: a TAXUS II, IV, V, and VI meta-analysis of 3445 patients followed for up to 3 years.J Am Coll Cardiol. 2007;49(10):1043-1051.

[5] Kelbaek H,Helqvist S,Thuesen L,et al. Sirolimus versus bare metal stent implantation in patients with total coronary occlusions: subgroup analysis of the Stenting Coronary Arteries in Non-Stress/Benestent Disease (SCANDSTENT) trial. Am Heart J.2006;152(5):882-886.

[6] Rahel BM,Laarman GJ,Kelder JC,et al.Three-year clinical outcome after primary stenting of totally occluded native coronary arteries: a randomized comparison of bare-metal stent implantation with sirolimus-eluting stent implantation for the treatment of total coronary occlusions (Primary Stenting of Totally Occluded Native Coronary Arteries [PRISON] II study). Am Heart J.2009;157(1):149-155.

[7] Hong MK,Mintz GS,Lee CW,et al. Paclitaxel coating reduces in-stent intimal hyperplasia in human coronary arteries: a serial volumetric intravascular ultrasound analysis from the Asian Paclitaxel-Eluting Stent Clinical Trial (ASPECT). Circulation.2003;107(4):517-520.

[8] Silber S,Gutierrez-Chico JL,Behrens S,et al. Effect of paclitaxel elution from reservoirs with bioabsorbable polymer compared to a bare metal stent for the elective percutaneous treatment of de novo coronary stenosis: the EUROSTAR-II randomised clinical trial. EuroIntervention.2011;7(1):64-73.

[9] Dibra A,Kastrati A,Mehilli J,et al.Paclitaxel-eluting or sirolimus-eluting stents to prevent restenosis in diabetic patients.N Engl J Med.2005;353(7):663-670.

[10] Morice MC,Serruys PW,Barragan P,et al. Long-term clinical outcomes with sirolimus-eluting coronary stents: five-year results of the RAVEL trial. J Am Coll Cardiol.2007; 50(14):1299-1304.

[11] Weisz G,Leon MB,Holmes DJ,et al. Two-year outcomes after sirolimus-eluting stent implantation: results from the Sirolimus-Eluting Stent in de Novo Native Coronary Lesions (SIRIUS) trial. J Am Coll Cardiol.2006;47(7):1350-1355

[12] 李浪.药物洗脱支架再狭窄后治疗方法的选择[J].中国循环杂志,2011,26(3):166-167.

[13] Ko YG,Kim JS,Kim BK,et al. Efficacy of Drug-Eluting Stents for Treating In-Stent Restenosis of Drug-Eluting Stents (from the Korean DES ISR Multicenter Registry Study [KISS]). Am J Cardiol. 2012;109(5):607-613.

[14] Kim YH,Lee BK,Park DW,et al. Comparison with conventional therapies of repeated sirolimus-eluting stent implantation for the treatment of drug-eluting coronary stent restenosis.Am J Cardiol.2006;98(11):1451-1454.

[15] Maluenda G,Ben-Dor I,Gaglia MJ,et al. Clinical outcomes and treatment after drug-eluting stent failure: the absence of traditional risk factors for in-stent restenosis. Circ Cardiovasc Interv.2012;5(1):12-19.

[16] Sousa JE,Costa MA,Abizaid A,et al.Sirolimus-eluting stent for the treatment of in-stent restenosis: a quantitative coronary angiography and three-dimensional intravascular ultrasound study.Circulation.2003;107(1):24-27.

[17] Steinberg DH,Gaglia MJ,Pinto ST,et al. Outcome differences with the use of drug-eluting stents for the treatment of in-stent restenosis of bare-metal stents versus drug-eluting stents. Am J Cardiol.2009;103(4):491-495.

[18] Cosgrave J,Melzi G,Corbett S,et al.Repeated drug-eluting stent implantation for drug-eluting stent restenosis: the same or a different stent. Am Heart J.2007;153(3):354-359.

[19] Garg S,Smith K,Torguson R,et al. Treatment of drug-eluting stent restenosis with the same versus different drug-eluting stent.Catheter Cardiovasc Interv.2007;70(1):9-14.

[20] Mehilli J,Byrne RA,Tiroch K,et al.Randomized trial of paclitaxel- versus sirolimus-eluting stents for treatment of coronary restenosis in sirolimus-eluting stents: the ISAR-DESIRE 2 (Intracoronary Stenting and Angiographic Results: Drug Eluting Stents for In-Stent Restenosis 2) study. J Am Coll Cardiol.2010;55(24):2710-2716.

[21] Lemos PA,van Mieghem CA,Arampatzis CA, et al. Post-sirolimus-eluting stent restenosis treated with repeat percutaneous intervention: late angiographic and clinical outcomes. Circulation.2004;109(21):2500-2502.

[22] Chatani K,Muramatsu T,Tsukahara R,et al.Predictive factors of re-restenosis after repeated sirolimus-eluting stent implantation for SES restenosis and clinical outcomes after percutaneous coronary intervention for SES restenosis. J Interv Cardiol.2009;22(4):354-361.

[23] Kang SJ,Mintz GS,Park DW,et al. Mechanisms of in-stent restenosis after drug-eluting stent implantation: intravascular ultrasound analysis. Circ Cardiovasc Interv.2011;4(1):9-14.

[24] 宋莉,颜红兵.药物洗脱支架再狭窄[J].中国介入心脏病学杂志, 2011,19(5):279-282.

[25] Inoue T,Node K.Molecular basis of restenosis and novel issues of drug-eluting stents. Circ J.2009；73(4):615-621.

[26] Yusuf RZ,Duan Z,Lamendola DE,et al.Paclitaxel resistance: molecular mechanisms and pharmacologic manipulation.Curr Cancer Drug Targets.2003;3(1):1-19.

[27] Huang S,Houghton PJ.Mechanisms of resistance to rapamycins Drug Resist Updat.2001;4(6):378-391.

[28] Huang S,Houghton PJ.Mechanisms of resistance to rapamycins. Drug Resist Updat.2001;4(6):378-391.

[29] Curcio A,Torella D,Indolfi C.Mechanisms of smooth muscle cell proliferation and endothelial regeneration after vascular injury and stenting: approach to therapy. Circ J.2011; 75(6): 1287-1296.

[30] Nebeker JR,Virmani R,Bennett CL,et al. Hypersensitivity cases associated with drug-eluting coronary stents: a review of available cases from the Research on Adverse Drug Events and Reports (RADAR) project. J Am Coll Cardiol.2006; 47(1):175-181.

[31] Balakrishnan B,Tzafriri AR,Seifert P,et al. Strut position, blood flow, and drug deposition: implications for single and overlapping drug-eluting stents. Circulation.2005;111(22): 2958-2965.

[32] Dangas GD,Claessen BE,Caixeta A,et al.In-stent restenosis in the drug-eluting stent era. J Am Coll Cardiol.2010; 56(23): 1897-1907.

[33] Mintz GS.Features and parameters of drug-eluting stent deployment discoverable by intravascular ultrasound. Am J Cardiol.2007;100(8B):26M-35M.

[34] Nayak AK,Kawamura A,Nesto RW,et al.Myocardial infarction as a presentation of clinical in-stent restenosis. Circ J.2006；70(8):1026-1029.

[35] Park CB,Hong MK,Kim YH,et al. Comparison of angiographic patterns of in-stent restenosis between sirolimus- and paclitaxel-eluting stent. Int J Cardiol.2007;120(3):387-390.

[36] Silber S,Colombo A,Banning AP,et al.Final 5-year results of the TAXUS II trial: a randomized study to assess the effectiveness of slow- and moderate-release polymer-based paclitaxel-eluting stents for de novo coronary artery lesions. Circulation.2009;120(15):1498-1504.

[37] Abizaid A,Costa JJ,Banning A,et al. The sirolimus-eluting Cypher Select coronary stent for the treatment of bare-metal and drug-eluting stent restenosis: insights from the e-SELECT (Multicenter Post-Market Surveillance) registry. JACC Cardiovasc Interv.2012;5(1):64-71.